AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

June 6, 2025

Study Completion Date

June 6, 2026

Conditions
Pancreatic Carcinoma
Interventions
DRUG

Toripalimab

Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks

DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks

DRUG

Nab paclitaxel

Nab paclitaxel 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.

OTHER

SBRT

SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions

Trial Locations (1)

210008

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

Fudan University

OTHER

collaborator

Shanghai Changzheng Hospital

OTHER

collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Xuzhou Central Hospital

OTHER

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT06080854 - AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter